Gliatech floats at $9.50 a share:
This article was originally published in Clinica
Executive Summary
At $9.50 a share, US company Gliatech lowered the price of shares in its initial public offering from the $11 assumed in the prospectus (see Clinica No 676, p 12). Selling 2.3 million shares, Gliatech raised around $20 million to be used for the manufacturing and marketing of the company's Adcon anti-adhesion products in Europe and clinical trials in the US and Europe